Shih‐Ping Liu
Papers
1
Total Citations
9
H-Index
1
About
Shih-Ping Liu is a leading urological researcher whose work focuses on improving the precision of prostate cancer diagnosis and treatment. His major contributions center on the clinical utility of novel biomarkers, particularly the prostate health index (PHI) and its derivative %p2PSA, to predict aggressive pathological outcomes in patients undergoing radical prostatectomy. In his highly cited 2020 study, Liu demonstrated that these biomarkers offer superior predictive accuracy for identifying clinically significant prostate cancer, helping to reduce unnecessary biopsies and overtreatment. With over 9 citations, this work has influenced risk-stratification protocols in urological oncology. Liu’s research bridges the gap between molecular diagnostics and surgical decision-making, providing clinicians with tools to better tailor treatment for organ-confined prostate cancer. His achievements include advancing the integration of PHI into preoperative assessment, which has the potential to improve patient outcomes by identifying those most likely to benefit from radical intervention. For students and researchers, Liu’s work exemplifies how targeted biomarker studies can translate into practical, patient-centered improvements in cancer care.
Research Focus
Key Achievements
Top Papers
- 1